KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Evet 98%
Piyasa kalitesi
45 / 100
Düşük kalite24s Hacim
₺36,3 B
Likidite
₺108,7 B
Düşük likiditeAlış / Satış
77.0% / 99.0%
Spread
22.0 pt
Geniş spreadPiyasa verileri
8 dakika önce güncellendi
17 Haz 26 21:00 UTC1 Oca 27 04:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketKurallar
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Uzlaşma kaynağı:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Sık sorulan sorular
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) için güncel oranlar nedir?
- Kalshi, 8 Eylül 2026 itibarıyla Yes için 98% fiyatlıyor.
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) ne zaman sonuçlanacak?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) için öngörülen sonuçlanma tarihi 1 Ocak 2027.
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.